enzh-TWfrdeitjaptrues

New combination drug regimens are being studied for the treatment of Waldenstrom macroglobulinemia (WM). In this segment, Dr. Jorge Castillo, MD, of Dana-Farber Cancer Institute updates patients on the information presented at the recent American Society of Hematology (ASH) conference and suggests that Waldenstrom patients pay attention to the combination of ibrutinib and rituximab (INNOVATE Study), that have shown faster and deeper responses over time versus rituximab alone.

Dr. Castillo also introduces LOXO-305, a BTK inhibitor and oral drug that was first presented for use in mantle cell lymphoma. He believes this could be a key area of study for Waldenstrom researchers in 2021.

https://patientpower.info/new-treatment-options-for-waldenstrom-macroglobulinemia/